Recruiting
Phase 2

Tremelimumab & Durvalumab

Sponsor:

The University of Texas Health Science Center at San Antonio

Code:

NCT06526104

Conditions

Hepatocellular Carcinoma

Cirrhosis, Liver

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Tremelimumab

Durvalumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information